This site is intended for healthcare professionals

Seagen + Genmab announce FDA filing acceptance for priority review of tisotumab vedotin BLA for patients with recurrent or metastatic cervical cancer.

Read time: 1 mins
Last updated:10th Apr 2021
Published:10th Apr 2021
Condition: Cervical Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest